Compare IART & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | ABUS |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.8M | 929.6M |
| IPO Year | 1996 | 2008 |
| Metric | IART | ABUS |
|---|---|---|
| Price | $13.91 | $4.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $14.33 | $5.00 |
| AVG Volume (30 Days) | 954.1K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.40 | $239.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $8.70 | $3.04 |
| 52 Week High | $16.42 | $5.10 |
| Indicator | IART | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 72.93 | 48.45 |
| Support Level | $12.90 | $4.17 |
| Resistance Level | $14.38 | $4.64 |
| Average True Range (ATR) | 0.71 | 0.17 |
| MACD | 0.37 | 0.01 |
| Stochastic Oscillator | 89.60 | 50.81 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.